$3.47
+0.03 (+0.73%)
ERNA News2 articles
Ernexa Therapeutics Soars 58% on Ovarian Cancer Therapy Hopes
Ernexa Therapeutics surged 58.5% on Tuesday after renewed investor interest in its preclinical ovarian-cancer cell therapy ERNA-101, though funding concerns persist.
Ernexa Therapeutics Surges 60% on Promising Ovarian Cancer Preclinical Data
Ernexa Therapeutics shares jumped about 60% after the company announced its ERNA-101 cell therapy plus PD-1 blockade eliminated tumors and achieved 100% long-term survival in preclinical ovarian cancer models.